Welcome to STN International! Enter x:X

LOGINID:SSPTANSC1625

## PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * *	* *	* *	* *	* Welcome to STN International * * * * * * * * * *
NEWS	1			Web Page for STN Seminar Schedule - N. America
NEWS		JUL	28	CA/CAplus patent coverage enhanced
NEWS	3	JUL	28	EPFULL enhanced with additional legal status
				information from the epoline Register
NEWS	4	JUL	28	IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS	5	JUL	28	STN Viewer performance improved
NEWS	6	AUG	01	INPADOCDB and INPAFAMDB coverage enhanced
NEWS	7	AUG	13	CA/CAplus enhanced with printed Chemical Abstracts
				page images from 1967-1998
NEWS	8	AUG	15	CAOLD to be discontinued on December 31, 2008
NEWS		AUG	15	CAplus currency for Korean patents enhanced
NEWS	10	AUG	27	CAS definition of basic patents expanded to ensure
				comprehensive access to substance and sequence
				information
NEWS	11	SEP	18	Support for STN Express, Versions 6.01 and earlier,
				to be discontinued
NEWS	12	SEP	25	CA/CAplus current-awareness alert options enhanced
				to accommodate supplemental CAS indexing of
				exemplified prophetic substances
NEWS	13	SEP	26	WPIDS, WPINDEX, and WPIX coverage of Chinese and
				and Korean patents enhanced
NEWS		SEP		IFICLS enhanced with new super search field
NEWS	15	SEP	29	EMBASE and EMBAL enhanced with new search and
117770	1.0	000	20	display fields
NEWS	Тр	SEP	30	CAS patent coverage enhanced to include exemplified prophetic substances identified in new Japanese-
				language patents
NEWS	17	OCT	0.7	EPFULL enhanced with full implementation of EPC2000
NEWS		OCT		Multiple databases enhanced for more flexible patent
MEMO	10	UCI	0 /	number searching
NEWS	10	OCT	22	Current-awareness alert (SDI) setup and editing
MEND	13	001	22	enhanced
NEWS	20	OCT	22	WPIDS, WPINDEX, and WPIX enhanced with Canadian PCT
HEND	20	001		Applications
NEWS	21	OCT	24	CHEMLIST enhanced with intermediate list of
112110				pre-registered REACH substances
				pro regrecered nation bubbleances
NEWS	EXP	RESS	JUN	E 27 08 CURRENT WINDOWS VERSION IS V8.3,
				CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.
NEWS	HOUE	RS	ST	N Operating Hours Plus Help Desk Availability
NEWS	LOGI	IN		lcome Banner and News Items
NEWS	IPC8	3	Fo:	r general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 10:40:28 ON 10 NOV 2008

=> fil reg COST IN U.S. DOLLARS FULL ESTIMATED COST

SINCE FILE TOTAL ENTRY SESSION 0.21 0.21

FILE 'REGISTRY' ENTERED AT 10:40:55 ON 10 NOV 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

COPIRIGHI (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 9 NOV 2008 HIGHEST RN 1071762-23-6
DICTIONARY FILE UPDATES: 9 NOV 2008 HIGHEST RN 1071762-23-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>

Uploading C:\Program Files\STNEXP\Queries\10559389.str

6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 27 28 ring/chain nodes:
1 2 3 4 5 chain bonds:
1 12 13 4 5 chain bonds:
1 12 13 4 5 chain bonds:
1 13 14 15 16 17 18 19 20 21 22 23 27 28 ring/chain bonds:
1 14 15 16 17 16 18 18 19 18

# G1:[\*1],[\*2]

chain nodes :

Match level: 1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS 10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 16:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS 27:CLASS 28:CLASS

### L1 STRUCTURE UPLOADED

=> d l1 L1 HAS NO ANSWERS L1 STR

Structure attributes must be viewed using STN Express query preparation.

=> s sss sam 11 SAMPLE SEARCH INITIATED 10:41:35 FILE 'REGISTRY' SAMPLE SCREEN SEARCH COMPLETED - 1376 TO ITERATE

100.0% PROCESSED 1376 ITERATIONS 0 ANSWERS SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*
BATCH \*\*COMPLETE\*\*
PROJECTED ITERATIONS: 25295 TO 29745
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=

Uploading C:\Program Files\STNEXP\Queries\10559389A.str

chain nodes :

1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS 10:CLASS 11:CLASS 12:CLASS 12:CLASS 12:CLASS 12:CLASS 12:CLASS 12:CLASS 12:CLASS 23:CLASS 27:CLASS 23:CLASS 27:CLASS 23:CLASS 27:CLASS 27:CLASS 23:CLASS 27:CLASS 27:

# L3 STRUCTURE UPLOADED

=> d le L3 HAS NO ANSWERS 'LE ' IS NOT A VALID STRUCTURE FORMAT KEYWORD ENTER STRUCTURE FORMAT (SIM), NOS:end

=> d 13 L3 HAS NO ANSWERS L3 STR

Structure attributes must be viewed using STN Express query preparation.

=> s sss sam 13 SAMPLE SEARCH INITIATED 10:44:13 FILE 'REGISTRY' SAMPLE SCREEN SEARCH COMPLETED - 2005 TO ITERATE 99.8% PROCESSED 2000 ITERATIONS 0 ANSWERS INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)


SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*
BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 37414 TO 42786
PROJECTED ANSWERS: 0 TO 0

L4 0 SEA SSS SAM L3

Uploading C:\Program Files\STNEXP\Queries\10559389B.str



chain nodes:
6 7 8 9 10 11 12 13 14 15
ring/chain nodes:
1 2 3 4 5

chain bonds :

1-11 1-12 2-14 2-15 5-6 5-13 6-7 6-8 6-9 9-10

ring/chain bonds : 1-2 1-5 2-3 4-5 exact/norm bonds :

1-2 1-5 2-3 4-5 9-10

exact bonds: 1-11 1-12 2-14 2-15 5-6 5-13 6-7 6-8 6-9

G1

Match level :


1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS 10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS

# L5 STRUCTURE UPLOADED

=> D L5

L5 HAS NO ANSWERS

L5 STR



Structure attributes must be viewed using STN Express query preparation.

=> S SSS SAM L5 SAMPLE SEARCH INITIATED 10:45:55 FILE 'REGISTRY' SAMPLE SCREEN SEARCH COMPLETED - 12924 TO ITERATE

15.5% PROCESSED 2000 ITERATIONS INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED) SEARCH TIME: 00.00.01 2 ANSWERS

PAGE 1-A

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*
BATCH \*\*COMPLETE\*\*
PROJECTED ITERATIONS: 251668 TO 265292
PROJECTED ANSWERS: 43 TO 473

L6 2 SEA SSS SAM L5

=> D SCAN

L6 2 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

Absolute stereochemistry. Rotation (-). Double bond geometry as shown.

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L6 2 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN 5-Undecanone, 3,7-bis[[(1,1-dimethylethyl)dimethylsilyl]oxy]-11-[(2R,3S)-3[(2S,3E)-2-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-3-methyl-4-(2-methyl-4thiazolyl)-3-buten-1-yl]-2-(fluoromethyl)-2-oxiranyl]-1-hydroxy-4,4,6,8tetramethyl-, (3S,6R,7S,8S)-

MF C45 H86 F N O6 S Si3

Absolute stereochemistry.

Double bond geometry as shown.

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ALL ANSWERS HAVE BEEN SCANNED

=> s sss FULL 11 FULL SEARCH INITIATED 10:47:48 FILE 'REGISTRY' FULL SCREEN SEARCH COMPLETED - 27721 TO ITERATE

100.0% PROCESSED 27721 ITERATIONS SEARCH TIME: 00.00.01 20 ANSWERS

L7 20 SEA SSS FUL L1

=> SAVE TEMP WEST10559389/A ENTER L#, L# RANGE, ALL, OR (END):END => SAVE TEMP WEST10559389/A L7 ANSWER SET L7 HAS BEEN SAVED AS 'WEST10559389/A'

=> FIL CAPLUS

COST IN U.S. DOLLARS SINCE FILE TOTAL ENTRY SESSION

183.88

184.09

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 10:48:41 ON 10 NOV 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 10 Nov 2008 VOL 149 ISS 20 FILE LAST UPDATED: 9 Nov 2008 (20081109/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

## http://www.cas.org/legal/infopolicy.html

=> S L7 L8

L8 8 L7

=> S L8 AND (AY<2003 OR PY<2003 OR PRY<2003)
4499665 AY<2003
22959179 PY<2003
3967969 PRY<2003

L9 4 L8 AND (AY<2003 OR PY<2003 OR PRY<2003)

=> D IBIB ABS HITSTR 1-4 L9

L9 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN ACCESSION NUMBER: 2003:511314 CAPLUS Full-text

DOCUMENT NUMBER: 139:85166

TITLE: Method for producing C1-C6 fragments of epothilones

and the derivatives thereof

INVENTOR(S): Klar, Ulrich; Berger, Markus; Buchmann, Bernd;

Schwede, Wolfgang; Skuballa, Werner PATENT ASSIGNEE(S): Schering Aktiengesellschaft, Germany

SOURCE: PCT Int. Appl., 30 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.			KIND DATE			APPLICATION NO.												
							WO 2002-EP14758											
	W:	ΑE,	AG,	AL,	AM,	AT,	AU,	AZ,	BA,	BB,	BG,	BR,	BY,	BZ,	CA,	CH,	CN,	
		CO,	CR,	CU,	CZ,	DK,	DM,	DZ,	EC,	EE,	ES,	FI,	GB,	GD,	GE,	GH,	GM,	
		HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KP,	KR,	KZ,	LC,	LK,	LR,	LS,	
		LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NO,	NZ,	OM,	PH,	PL,	
		PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	TJ,	TM,	TN,	TR,	TT,	TZ,	UA,	
		UG,	UZ,	VC,	VN,	YU,	ZA,	ZM,	ZW									
	RW:	GH,	GM,	KE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	AZ,	BY,	
		KG,	KZ,	MD,	RU,	TJ,	TM,	AT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,	
		FI,	FR,	GB,	GR,	ΙE,	IT,	LU,	MC,	NL,	PT,	SE,	SI,	SK,	TR,	BF,	BJ,	
		CF,	CG,	CI,	CM,	GA,	GN,	GQ,	GW,	ML,	MR,	NE,	SN,	TD,	TG			
DE	1016	4592			A1		2003	0703		DE 2	001-	1016	4592		2	0011	221 <	
AU	2002	3567	83		A1		2003	0709		AU 2	002-	3567	83		2	0021	223 <	
US 20030176710				A1		2003	0918		US 2	002-	3262	63		2	0021	223 <		
PRIORITY APPLN. INFO.:								DE 2	001-	1016	4592		A 2	0011	221 <			
										WO 2	002-	EP14	758		W 2	0021	223 <	
OTHER SOURCE(S): GI				CAS	REAC	T 13	9:85	166;	MAR	PAT	139:	8516	6					

AB The invention relates to C1-C6 fragments I [R1a, R1b = H, C1-10-alkyl, aryl, C7-20-aralkyl, (CH2)m; m = 2 - 5; R2a, R2b = H, C1-10-alkyl, C1-10-alkeyl, C1-10-alkyl, (CH2)m; m = 2 - 5; R15a, R15b = H, C1-10-alkyl, aryl, C7-20-aralkyl, (CH2)q; q = 3 - 6] of epothilones and to an efficient method for producing such fragments and the derivs. thereof. Thus, (4S)-4-(2-methyl-3-oxohept-6-en-2-yl)-2, 2-dimethyl-1,3- dioxane [I; R1a = R1b = Me, R2a = CH2CH:CH2, R2b = H, R15a = R15b = Me] was prepared from (3S)-1-hydroxy-2,2-dimethyl-3-(tetrahydropyranyloxy)-4- pentene, (S)-HOCH2CMe2CH(OTHP)CH:CH2, via O-benzylation with PECH2Br, hydroboration with BH3-THF complex, dehydrotetrahydropyranylation-isopropylidenation with MeC(OMe)2 in MeCOMe containing catalytic tosyl acid, hydrogenolytic debenzylation, Swern oxidation, Grignard reaction with MeMgBr, oxidn, with TPAT in CH2C12 contg, NOmethylmorpholine N-oxide and alkylation with allyl bromide.

IT 305840-13-5F 552213-46-9F 552313-55-0F 552313-56-1F 552313-65-2F 552313-66-3F 552313-76-5F 552213-77-6F 552313-87-8F 552313-88-9F 552313-98-1F 552213-99-2F

RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of C1-C6 fragments of epothilones and their derivs.)

RN 305840-13-5 CAPLUS

CN 6-Hepten-3-one, 2-[(4S)-2,2-dimethyl-1,3-dioxan-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

RN 552313-46-9 CAPLUS

CN 6-Octen-3-one, 2-[(4S)-2,2-dimethyl-1,3-dioxan-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.

RN 552313-55-0 CAPLUS

CN 6-Hepten-3-one, 2-(7S)-6,10-dioxaspiro[4.5]dec-7-yl-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.

RN 552313-56-1 CAPLUS

CN 6-Octen-3-one, 2-(7S)-6,10-dioxaspiro[4.5]dec-7-yl-2-methyl- (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry unknown.

RN 552313-65-2 CAPLUS

CN 6-Hepten-3-one, 2-(2S)-1,5-dioxaspiro[5.5]undec-2-yl-2-methyl- (CA INDEX NAME) Absolute stereochemistry.

RN 552313-66-3 CAPLUS

CN 6-Octen-3-one, 2-(2S)-1,5-dioxaspiro[5.5]undec-2-y1-2-methy1- (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry unknown.

RN 552313-76-5 CAPLUS

CN 6-Hepten-3-one, 2-methyl-2-[(4S)-2-phenyl-1,3-dioxan-4-yl]- (CA INDEX NAME)

Absolute stereochemistry.

RN 552313-77-6 CAPLUS

CN 6-Octen-3-one, 2-methyl-2-[(4S)-2-phenyl-1,3-dioxan-4-yl]- (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry unknown.

RN 552313-87-8 CAPLUS

CN 6-Hepten-3-one, 2-[(4S)-2-(4-methoxyphenyl)-1,3-dioxan-4-yl]-2-methyl-(CA INDEX NAME)

Absolute stereochemistry.

RN 552313-88-9 CAPLUS

CN 6-Octen-3-one, 2-[(4S)-2-(4-methoxyphenyl)-1,3-dioxan-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry unknown.

RN 552313-98-1 CAPLUS

CN Benzonitrile, 2-[(4S)-4-(1,1-dimethyl-2-oxo-5-hexen-1-yl)-1,3-dioxan-2-yl]-(CA INDEX NAME)

Absolute stereochemistry.

RN 552313-99-2 CAPLUS

CN Benzonitrile, 2-[(4S)-4-(1,1-dimethyl-2-oxo-5-hepten-1-yl)-1,3-dioxan-2yl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

## RECORD, ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:133222 CAPLUS <u>Full-text</u> DOCUMENT NUMBER: 138:187562

TITLE:

Preparation of protected

3,5-dihydroxy-2,2-dimethyl-valeroamides as

intermediates for the synthesis of epothilones and derivatives

INVENTOR(S): Westermann, Juergen; Petrov, Orlin; Platzek, Johannes

PATENT ASSIGNEE(S): Schering Aktiengesellschaft, Germany

PCT Int. Appl., 51 pp. SOURCE:

CODEN: PIXXD2

DOCUMENT TYPE:

Patent LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1 PATENT INFORMATION:

TENT	TIME OF	(IIMII	OIN
PA	TENT	NO.	

PA	TENT NO.	KI	ID DATE	APPLICATION NO.	DATE		
WO	2003014063	A	20030220	WO 2002-EP8726	20020805 <		
WO	2003014063	A:	20030501				
	W: AE, AG,	AL, AM	AT, AU, AZ,	BA, BB, BG, BR, BY,	BZ, CA, CH, CN,		
	CO, CR,	CU, CZ	DK, DM, DZ,	EC, EE, ES, FI, GB,	GD, GE, GH, GM,		
	HR, HU,	ID, IL	IN, IS, JP,	KE, KG, KP, KR, KZ,	LC, LK, LR, LS,		
				MN, MW, MX, MZ, NO,			
	PT, RO,	RU, SD	SE, SG, SI,	SK, SL, TJ, TM, TN,	TR, TT, TZ, UA,		
			ZA, ZM, ZW				
	RW: GH, GM,	KE, LS	MW, MZ, SD,	SL, SZ, TZ, UG, ZM,	ZW, AM, AZ, BY,		
	KG, KZ,	MD, RU	TJ, TM, AT,	BE, BG, CH, CY, CZ,	DE, DK, EE, ES,		
	FI, FR,	GB, GR	IE, IT, LU,	MC, NL, PT, SE, SK,	TR, BF, BJ, CF,		
				ML, MR, NE, SN, TD,			
DE	10138348	A	20030227	DE 2001-10138348	20010803 <		
CA	2456255	A	20030220	CA 2002-2456255	20020805 <		
AU	2002340805	A	20030224	AU 2002-340805	20020805 <		
US	20030158412	A	20030821	1 US 2002-211242 2002080			
US	6933385	B	A1 20030224 AU 2002-340805 200208 A1 20030821 US 2002-211242 200208 B2 20050823 A2 20040428 EP 2002-774500 200208				
EP	1412322	A:	20040428	EP 2002-774500	20020805 <		
	R: AT, BE,	CH, DE	DK, ES, FR,	GB, GR, IT, LI, LU,	NL, SE, MC, PT,		
	IE, SI,	LT, LV	FI, RO, MK,	CY, AL, TR, BG, CZ,	EE, SK		
BR	2002011649	A	20040713	BR 2002-11649	20020805 <		
CN	1538952	A	20041020	CN 2002-815237	20020805 <		
JP	2004537589	T	20041216	JP 2003-519015	20020805 <		
CN	1807403	A	20060726	CN 2005-10076459 MX 2004-PA954 IN 2004-DN467 NO 2004-912 ZA 2004-1727	20020805 <		
MX	2004PA00954	A	20040420	MX 2004-PA954	20040130 <		
IN	2004DN00467	A	20060310	IN 2004-DN467	20040226 <		
NO	2004000912	A	20040302	NO 2004-912	20040302 <		
ZA	2004001727	A	20050412	ZA 2004-1727	20040302 <		
US	20050272731	A:	20051208	US 2005-149331	20050610 <		
US	7368568	В:	20080506				
US	20080161580	A	20080703	US 2008-43401	20080306 <		
	Y APPLN. INFO			DE 2001-10138348	A 20010803 <		
				US 2001-313015P	P 20010820 < A3 20020805 < A3 20020805 <		
				CN 2002-815237	A3 20020805 <		
				US 2002-211242	A3 20020805 <		
				WO 2002-EP8726	W 20020805 <		
				US 2005-149331	A3 20050610		

OTHER SOURCE(S):

- AB The present invention discloses preparation of novel protected 3,5-dihydroxy-2,2-dimethyl-valeroamide derivs., such as I [R1, R2 = benzyl, 4-methoxybenzyl, 3,4-dimethoxybenzyl, THP, TBDMS, TMS, TES, TIP, TBDPS, MEM, MOM, allyl, tritvl; R1R2 = ketal; Y = NA1A2; A1, A2 = alkvl, arvl, benzvl, OH, OMe, Obenzyl, heterocyclyl], and intermediates thereof for the synthesis of epothilones and epothilone derivs. Thus, 1-dimethylamino-2-methyl-1trimethylsilyl-propene (obtained by the reaction of N,N,2-trimethylpropionamide and trimethylsilyl chloride), was reacted with 3-(benzyloxy)-1propanal to provide N, N-dimethyl-5-benzyloxy-2, 2-dimethyl-3hydroxypentanamide, which on oxidation afforded N,N-dimethyl-5-benzyloxy-2,2dimethyl-3-oxo-pentanamide (II). II, on catalytic reduction in presence of RuC12 and S-BiNAP, afforded I (R1 = CH2Ph; R2 = H; Y = NMe2), which was deprotected to afford I [R1, R2 = H; Y = NMe2 (III)]. III was reacted with acetone-dimethylketal to afford 3,5-dihydroxy-2,2-dimethyl-valeroamide derivative (IV).
- IT 305640-13-5P
  RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP
  (Preparation)

(preparation of protected 3,5-dihydroxy-2,2-dimethyl-valeroamide derivs.

and intermediates thereof in preparation of epothilones and epothilone derivs.) RN 305840-13-5 CAPLUS

CN 6-Hepten-3-one, 2-[(4S)-2,2-dimethyl-1,3-dioxan-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

L9 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN ACCESSION NUMBER: 2002:157050 CAPLUS Full-text

DOCUMENT NUMBER: 136:216592

TITLE: Procedures for the production of

12,13-cyclopropylepothilone derivatives, as well as

for their use in pharmaceutical preparations

PATENT ASSIGNEE(S): Schering Ag, Germany SOURCE: Ger. Offen., 64 pp.

CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

#### PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10041470	A1	20020228	DE 2000-10041470	20000818 <
PRIORITY APPLN. INFO.:			DE 2000-10041470	20000818 <
OTHER SOURCE(S):	CASREA	CT 136:21659	92; MARPAT 136:216592	

$$X^1 = (CH_2)_m - (CH_2)_{pR^{26}}$$

$$X^2 = (CH_2)_m - (CH_2)_p R^{26}$$

AB The present invention describes new 6-alkenyl- and 6-alkynylepothilone derivs., e.g., I [Rla, Rlb = H, C1-10-alkyl, aryl, C7-20-aralkyl; RlaRlb = (CH2)r, CH2OCH2; r = 1 - 5; R2a = H, C1-10-alkyl, aryl, C7-20-aralkyl, (CH2)m-C.tplbond.C-(CH2)pR26, (CH2)m-C:C-(CH2)pR26, X1, X2; n = 0 - 5; p = 0 - 3; m = 0 - 5; p = 0 - 3; m = 0 - 5; p = 0 - 3; m = 0 - 5; p = 0 - 3; m = 0 - 5; p = 0 - 3; m = 0 - 5; p = 0 - 3; m = 0 - 5; p = 0 - 3; m = 0 - 5; p = 0 - 3; m = 0 - 5; p = 0 - 3; m = 0 - 5; p = 0 - 3; m = 0 - 5; p = 0 - 3; m = 0 - 5; p = 0 - 3; m = 0 - 5; p = 0 - 3; m = 0 - 5; p = 0 - 3; p0 - 4; R2b = (CH2)m-C.tplbond.C-(CH2)pR26, (CH2)m-C:C-(CH2)pR26, X1, X2; R3a = H, C1-10-alkvl, arvl, C7-20-aralkvl; R3b = 0-protecting group; R4 = H, C1-10alkyl, aryl, C7-20-aralkyl, halogen, OH, O-protecting group, CN; R5 = H, C1-10-alkyl, aryl, C7-20-aralkyl, (CH2)s-T; S=1-4; T=OH, O-protecting group, halogen; R6R7 = C(R33)2, NR32 AY = OC(:0), OCH2, CH2C(:0), NR29C(:0), NR29SO2; DE = CH2CH2, CH2O, OCH2; G = X:CR8-, bicyclic or tricyclic aryl; X = O, (O-alkyl)2, etc.; Z = H, H,OH, H,O-protective group; R8 = H, halogen, CN, C1-20-alkyl, arvl, C7-20-aralkyl; R14 = H, OH, halogen, O-SO2-alkyl, O-SO2arvl, O-SO2-aralkvl; R26 = H, C1-10-alkvl, arvl, C7-20-aralkvl, C1-10-acvl, OH, O-protecting group; R29 = H, C1-20-alky1; R32 = H, C1-4-alky1, C1-4-acy1; R33 = H, halogen], which interact with tubulins by stabilizing the formed microtubulins (no data). I are able specifically to affect cell division and are suitable, for example for the treatment of malignant tumors ovarial -, stomach -, colon -, adeno -, chest -, lungs -, head and neck carcinoma, malignant melanoma, acute lymphocytic and myelocytic leukemia. In addition I are suitable for the anti-angiogenesis therapy as well as for the treatment of chronic ignitable illnesses (psoriasis, arthritis). For the avoidance of uncontrolled cell rampant growths on as well as the better compatibility of medical implants I can be up and/or brought into polymers materials. According to invention, I can be used alone or for the achievement of additive or synergistic effects in combination with further principles and substance classes applicable in the tumor therapy. Exptl. data from patents PCT/EP00/01333 and PCT/IB00/00657 are reproduced here.

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 12,13-cyclopropylepothilone derivs. and their use in pharmaceutical compns.)

RN 305840-13-5 CAPLUS

CN 6-Hepten-3-one, 2-[(4S)-2,2-dimethyl-1,3-dioxan-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

L9 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:790507 CAPLUS Full-text

DOCUMENT NUMBER: 133:362656

TITLE: Preparation of 6-alkenyl-, 6-alkynyl- and

6-epoxyepothilone derivatives and their antitumor

activity

INVENTOR(S): Klar, Ulrich; Schwede, Wolfgang; Skuballa, Werner; Buchmann, Bernd; Hoffmann, Jens; Lichtner, Rosemarie

PATENT ASSIGNEE(S): Schering Aktiengesellschaft, Germany

SOURCE: PCT Int. Appl., 298 pp.

CODEN: PIXXD2

A

DOCUMENT TYPE: Patent

LANGUAGE: English FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

NZ 514989

PATENT NO. KIND DATE APPLICATION NO. DATE WO 2000066589 20001109 WO 2000-IB657 20000501 <--A1 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG DE 19921086 A1 20001102 DE 1999-19921086 19990430 <--DE 19954228 A1 20010913 DE 1999-19954228 19991104 <--DE 10015836 A1 20011011 DE 2000-10015836 20000327 <--CA 2371226 A1 20001109 CA 2000-2371226 20000501 <--BR 2000010190 A 20020108 BR 2000-10190 20000501 <--EP 1173441 A1 20020123 EP 2000-922826 20000501 <--R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, MC, PT, IE, SI, LT, LV, FI, RO JP 2002543203 T 20021217 JP 2000-615619 20000501 <--JP 4024003 B2 20071219 EE 200100568 A 20030217 EE 2001-568 20000501 <--

20040227 NZ 2000-514989

20000501 <--

AU 772750	B2	20040506	AU	2000-43103		20000501	<
IN 2001MN01305	A	20070504	IN	2001-MN1305		20011019	<
BG 106053	A	20020531	BG	2001-106053		20011026	<
NO 2001005278	A	20011221	NO	2001-5278		20011029	<
MX 2001PA11039	A	20030630	MX	2001-PA11039		20011030	<
US 7125893	B1	20061024	US	2002-979939		20020606	<
IN 2005MN00837	A	20070608	IN	2005-MN837		20050802	<
US 20060046997	A1	20060302	US	2005-214988		20050831	<
PRIORITY APPLN. INFO.:			DE	1999-19921086	A1	19990430	<
			DE	1999-19954228	A1	19991104	<
			DE	2000-10015836	A1	20000327	<
			DE	2000-10013363	Α	20000309	<
			WO	2000-IB657	W	20000501	<
			IN	2001-MN1305	A3	20011019	<
			US	2002-979939	A3	20020606	<

OTHER SOURCE(S): MARPAT 133:362656

GI

- \* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY AVAILABLE VIA OFFLINE PRINT \*
- AB The antitumor agents, 6-alkenyl-, 6-alkynyl- and 6-epoxyepothilones I (R1a, Rlb are same or different = H. C1-C10 alkyl, C6-C12 aryl, C7-C20 aralkyl each optionally substituted; or together = (CH2)m m = 1-5 or -CH2OCH2-; R2a(R2b replace a with b) = H, substituted alkyl, aryl, aralkyl, (CH2)ra-C.tplbond.(or =)C-(CH2)pa-R26a, Q, Q1 where n = 0-5; ra, rb = the same or different and = 0-4; pa, pb = the same or different and = 0-3; R3a = H, substituted alkyl, aryl or aralkv1; R3b = OH, OPG14; R14 = H, OR14a, halogen and R14a = H, SO2-alkv1, SO2-aryl or SO2-aralkyl; R4 = H, substituted alkyl, aryl or aralkyl, halogen, OR25, CN; R26a, R26b = same or different = H, substituted alkyl, aryl or aralkyl, C1-C10 acyl or if pa or pb > 0, addnl. a group OR27; R25 = R27 = R22 = H, PG; R5 = H, substituted alkyl, aryl or aralkyl, (CH2)sT s = 1-4, T = OR22 or halogen; R6, R7 = H or together = bond or O; G = X=CR8 or bi- or tricyclic arvl radical and R8 = H, halogen, CN, or substituted alkyl, aryl or aralkyl; X = 0, two OR23 groups, C2-C10-alkylene- $\alpha$ ,  $\omega$ -dioxy straight chain or branched; H/OR9 or CR10R11 group and R23 = alkyl radical, R9 = H, PG, R10,R11 = same or different = H, substituted alkyl, aryl or aralkyl, or together with the methylene are a 5-7 carbocyclic ring; D-E = CH2CH2 or OCH2; A = OC(O), OCH2, CH2C(0), NR29C(0), NR29S02 and R29 = H, alkyl; Z = 0 or H/OR12 and R12 = H, PG) were prepared. Thus II was prepared in a multistep synthesis starting from (4S)-4-(2-methyl-1-oxoprop-2-yl)-2,2- dimethyl[1,3]dioxane and 5trimethylsilylpent-4-in-1-yl magnesium bromide. II had an IC50 value [nM] of 3.0 for the growth inhibition of human MCF-7 breast- and 75 for multidrug resistant NCI/ADR carcinoma cell lines with a selectivity of 2.5. The new epothilone derivs. interact with tubulin by stabilizing microtubuli that are formed. They are able to influence the cell-splitting in a phase-specific manner and are therefore useful in treating diseases or conditions associated with the need for cell growth, division and/or proliferation. Thus the epothilone derivs. are suitable for treating malignant tumors, e.g., ovarian, stomach, colon, adeno-, breast, lung, head and neck carcinomas, malignant melanoma, acute lymphocytic and myelocytic leukemia; and for anti-angiogenesis therapy as well as for treatment of chronic inflammatory diseases (such as psoriasis, arthritis).
- IT 305840-13-5P
  - RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
    - (preparation of 6-alkenyl-, 6-alkynyl- and 6-epoxyepothilone derivs. and their use in pharmaceutical prepns.)

RN 305840-13-5 CAPLUS

CN 6-Hepten-3-one, 2-[(4S)-2,2-dimethyl-1,3-dioxan-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD, ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> LOGOFF Y COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL
FULL ESTIMATED COST	34.40	218.49
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL
CA SUBSCRIBER PRICE	-3.20	-3.20

STN INTERNATIONAL LOGOFF AT 10:56:11 ON 10 NOV 2008